RMD Open (Sep 2022)
Prolonged COVID-19 symptom duration in people with systemic autoimmune rheumatic diseases: results from the COVID-19 Global Rheumatology Alliance Vaccine Survey
- Francis Berenbaum,
- Jasvinder A Singh,
- Ali Duarte-García,
- Jinoos Yazdany,
- Pedro M Machado,
- Namrata Singh,
- Deshire Alpizar-Rodriguez,
- Zachary S Wallace,
- Eimear Duff,
- Rebecca Grainger,
- Tamer A Gheita,
- Elizabeth R Graef,
- Jean W Liew,
- Michael S Putman,
- Julia F Simard,
- Emily Sirotich,
- Carly Harrison,
- Philip C Robinson,
- Sebastian E Sattui,
- Jeffrey A Sparks,
- Gary Foster,
- Suleman Bhana,
- Wendy Costello,
- Jonathan S Hausmann,
- Paul Sufka,
- Richard Conway,
- Akpabio Akpabio,
- Michal Nudel,
- Manuel F Ugarte-Gil,
- Michael DiIorio,
- Mitchell Levine,
- Evelyn Hsieh,
- Richard A Howard,
- John Wallace,
- Inita Bulina,
- Kevin Kennedy,
- Tarin T Moni,
- Aman Dev Singh,
- Lina El Kibbi,
- Chieh Lo,
- David FL Liew,
- Monique Gore-Massy,
- Maggie J Larché,
- More A Kodhek,
- Nadine Lalonde,
- Laura-Ann Tomasella,
- Richard P Beesley,
- Eugenia Yupei Chock
Affiliations
- Francis Berenbaum
- INSERM CRSA, Sorbonne University, Paris, France
- Jasvinder A Singh
- 1 Department of Medicine, University of Alabama at Birmingham, Birmingham, Alabama, USA
- Ali Duarte-García
- 1 Department of Internal Medicine, Division of Rheumatology, Mayo Clinic, Rochester, Minnesota, USA
- Jinoos Yazdany
- Division of Rheumatology, Department of Medicine, University of California, San Francisco, San Francisco, California, USA
- Pedro M Machado
- 3 Centre for Rheumatology & Department of Neuromuscular Diseases, University College London, London, UK
- Namrata Singh
- Department of Hematology, Post Graduate Institute of Medical Education and Research, Chandigarh, India
- Deshire Alpizar-Rodriguez
- Research Unit, Mexican College of Rheumatology, Coyoacan, Mexico
- Zachary S Wallace
- 2 Clinical Epidemiology Program, Division of Rheumatology, Allergy and Immunology, Massachusetts General Hospital, Boston, Massachusetts, USA
- Eimear Duff
- Department of Rheumatology, Saint James`s Hospital, Dublin, Ireland
- Rebecca Grainger
- Department of Medicine, University of Otago, Wellington, New Zealand
- Tamer A Gheita
- Rheumatology and Clinical Immunology, Faculty of Medicine, Cairo University, Cairo, Egypt
- Elizabeth R Graef
- 7 Division of Rheumatology and Clinical Immunology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts, USA
- Jean W Liew
- Section of Rheumatology, Boston University School of Medicine, Boston, Massachusetts, USA
- Michael S Putman
- 3 Department of Medicine, Division of Rheumatology, Feinberg School of Medicine, Northwestern University, Chicago, Illinois, USA
- Julia F Simard
- Department of Epidemiology & Population Health, Stanford University School of Medicine, Stanford, California, USA
- Emily Sirotich
- Department of Health Research Methods, Evidence, and Impact, McMaster University, Hamilton, Ontario, Canada
- Carly Harrison
- LupusChat, New York, New York, USA
- Philip C Robinson
- School of Clinical Medicine, The University of Queensland, Herston, Queensland, Australia
- Sebastian E Sattui
- 15 Division of Rheumatology, Hospital for Special Surgery, New York, New York, USA
- Jeffrey A Sparks
- Division of Rheumatology, Immunology and Allergy, Brigham and Women`s Hospital, Boston, Massachusetts, USA
- Gary Foster
- Department of Health Research Methods, Evidence, and Impact (HEI); Medicine, McMaster University, Hamilton, Ontario, Canada
- Suleman Bhana
- Pfizer, Inc, New York, New York, USA
- Wendy Costello
- Irish Children`s Arthritis Network (iCAN), Tipperary, Ireland
- Jonathan S Hausmann
- Department of Medicine, Harvard Medical School, Boston, Massachusetts, USA
- Paul Sufka
- Healthpartners, St Paul, Minnesota, USA
- Richard Conway
- Rheumatology, Saint James`s Hospital, Dublin, Ireland
- Akpabio Akpabio
- Rheumatology, Sheffield Teaching Hospitals NHS Foundation Trust, Sheffield, UK
- Michal Nudel
- The Israeli Association for RMD Patients Mifrakim Tz`eirim, Haifa, Israel
- Manuel F Ugarte-Gil
- School of Medicine, Universidad Cientifica del Sur, Lima, Peru
- Michael DiIorio
- Department of Medicine, Brigham and Women`s Hospital, Boston, Massachusetts, USA
- Mitchell Levine
- Department of Health Research Methods, Evidence and Impact (HEI), McMaster University Faculty of Health Sciences, Hamilton, Ontario, Canada
- Evelyn Hsieh
- Section of Rheumatology, Allergy & Immunology, Yale School of Medicine, New Haven, Connecticut, USA
- Richard A Howard
- Spondylitis Association of America, Van Nuys, California, USA
- John Wallace
- Autoinflammatory UK, Edinburgh, UK
- Inita Bulina
- Department of Internal Diseases, Rheumatology Centre, Paul Stradins Clinical University Hospital, Riga, Latvia
- Kevin Kennedy
- Health Research Methods, Evidence, and Impact, McMaster University, Hamilton, Ontario, Canada
- Tarin T Moni
- Department of Biochemistry & Biomedical Sciences, McMaster University Faculty of Science, Hamilton, Ontario, Canada
- Aman Dev Singh
- Community Medicine, GMC Patiala, Punjab, India
- Lina El Kibbi
- Rheumatology, Specialized Medical Center Hospital, Riyadh, Saudi Arabia
- Chieh Lo
- I-Shou University College of Medicine, Yanchau Sheng, Taiwan
- David FL Liew
- Department of Medicine, The University of Melbourne, Melbourne, Victoria, Australia
- Monique Gore-Massy
- Lupus Foundation of America, Washington, DC, USA
- Maggie J Larché
- Divisions of Clinical Immunology and Allergy/Rheumatology, McMaster University Department of Medicine, Hamilton, Ontario, Canada
- More A Kodhek
- Lupus Foundation of Kenya, Nairobi, Kenya
- Nadine Lalonde
- Patient Board, Covid-19 Global Rheumatology Alliance, London, Ontario, Canada
- Laura-Ann Tomasella
- Arthritis Kids South Africa, Johannesburg, South Africa
- Richard P Beesley
- Juvenile Arthritis Research, European Network for Childhood Arthritis (ENCA), Tonbridge, UK
- Eugenia Yupei Chock
- Section of Rheumatology, Yale School of Medicine, New Haven, Connecticut, USA
- DOI
- https://doi.org/10.1136/rmdopen-2022-002587
- Journal volume & issue
-
Vol. 8,
no. 2
Abstract
Objective We investigated prolonged COVID-19 symptom duration, defined as lasting 28 days or longer, among people with systemic autoimmune rheumatic diseases (SARDs).Methods We analysed data from the COVID-19 Global Rheumatology Alliance Vaccine Survey (2 April 2021–15 October 2021) to identify people with SARDs reporting test-confirmed COVID-19. Participants reported COVID-19 severity and symptom duration, sociodemographics and clinical characteristics. We reported the proportion experiencing prolonged symptom duration and investigated associations with baseline characteristics using logistic regression.Results We identified 441 respondents with SARDs and COVID-19 (mean age 48.2 years, 83.7% female, 39.5% rheumatoid arthritis). The median COVID-19 symptom duration was 15 days (IQR 7, 25). Overall, 107 (24.2%) respondents had prolonged symptom duration (≥28 days); 42/429 (9.8%) reported symptoms lasting ≥90 days. Factors associated with higher odds of prolonged symptom duration included: hospitalisation for COVID-19 vs not hospitalised and mild acute symptoms (age-adjusted OR (aOR) 6.49, 95% CI 3.03 to 14.1), comorbidity count (aOR 1.11 per comorbidity, 95% CI 1.02 to 1.21) and osteoarthritis (aOR 2.11, 95% CI 1.01 to 4.27). COVID-19 onset in 2021 vs June 2020 or earlier was associated with lower odds of prolonged symptom duration (aOR 0.42, 95% CI 0.21 to 0.81).Conclusion Most people with SARDs had complete symptom resolution by day 15 after COVID-19 onset. However, about 1 in 4 experienced COVID-19 symptom duration 28 days or longer; 1 in 10 experienced symptoms 90 days or longer. Future studies are needed to investigate the possible relationships between immunomodulating medications, SARD type/flare, vaccine doses and novel viral variants with prolonged COVID-19 symptoms and other postacute sequelae of COVID-19 among people with SARDs.
